A Phase I Study of Nifurtimox in Patients with Relapsed/Refractory Neuroblastoma
Saulnier Sholler G, Bergendahl G, Brard L, Singh AP, Heath B, Bingham P, Ashikaga T, Kamen B, Homans A, Slavik M, Lenox S, Higgins T, Ferguson W. A Phase I Study[...]
Synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II
Saulnier Sholler G, Currier E, Bachmann A. Synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden
Bortezomib and HDAC inhibitor PCI24781 show synergistic activity in neuroblastoma in vitro and in vivo models, inducing ROS and depressing MYCN
Currier E, Illenye S, Libous J, Bond J, Lescault P, Saulnier Sholler G. Bortezomib and HDAC inhibitor PCI24781 show synergistic activity in neuroblastoma in vitro and in vivo models, inducing ROS and depressing MYCN. June 2010[...]
An unexpected finding: Genomic profiling of neuroblastoma predicts tamoxifen as a potential therapy and is confirmed in vitro and in vivo
Eslin D, Currier E, Illenye S, Bond J, Webb C, Saulnier Sholler G. An unexpected finding: Genomic profiling of neuroblastoma predicts tamoxifen as a potential therapy and is confirmed in vitro[...]
BTK expression is critical in Neuroblastoma Tumor Initiating Cells
Currier E, Illenye S, Dorf L, Honigberg L, Saulnier Sholler G. BTK expression is critical in Neuroblastoma Tumor Initiating Cells. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden
A phase I trial of TPI-287 as a single agent and it combination with temozolomide in relapsed neuroblastoma or medulloblastoma
Saulnier Sholler G, Bergendahl G, Lenox S, Zage P, Roberts W, Kraveka J, Eslin D, Kaplan J, Higgins T, Ferguson T. A phase I trial of TPI-287 as a single agent and[...]
Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model. Chem Biol Drug
Lange TS, Zou Y, Singh RK, Kim KK, Kristjansdottir K, Sholler GL, Brard L. Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model. Chem Biol Drug Des. 2010 Aug;76(2):164-73. doi: 10.1111/j.1747-0285.2010.00988.x.[...]
Bortezomib and HDAC inhibitor PCI-24781 combination therapy for Neuroblastoma
Currier E, Illenye S, Ashikaga T, Lescault P, Bond J and Saulnier Sholler G. Bortezomib and HDAC inhibitor PCI-24781 combination therapy for Neuroblastoma. April 2010 AACR Annual Meeting, Washington DC
Neuroblastoma: a spectrum of cells isolated from bone marrow of patients
Saulnier Sholler G, Illenye S, Warzynski M, Brown RE, Lescault PJ, Koto K, Dorf L, Bond J. Neuroblastoma: a spectrum of cells isolated from bone marrow of patients. May 2009 ASCO Annual[...]
Increased cytotoxicity with nifurtimox and rapamycin combination therapy in neuroblastoma
Dorf L, Brard L, Koto K, Illenye S, Ashikaga T, Singh R, Kim K, Saulnier Sholler G. Increased cytotoxicity with nifurtimox and rapamycin combination therapy in neuroblastoma. April 2009, AACR Annual Meeting, Denver,[...]